Category: Health Science
-
Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection
-
That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster
“There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system,” stated Pierre Laurin, CEO of Ingenew, who added that it could “potentially fight off symptoms associated with coronaviruses.”
-
PredictMedix (PMED.C) to deploy its COVID-19 screening tech in Texas
Institutional failure at every level of decision making in the United States is why COVID-19 in the world’s largest economy is neither contained nor controlled. A healthy reminder – no matter how bad things are, they can always get worse. With over 6 million active cases and 186K+ deaths, the pandemic is a nightmare that…
-
Plurilock Technologies: Disrupting Biometric Cybersecurity
The new economy is digital. It’s in the trillions, so increasing digitization of the world has led to an increased risk that some parts of the ecosystem will be compromised. It’s no surprise then, that a ton of cybersecurity firms have emerged and attempted to dominate the landscape of ensuring and maintaining data privacy. However,…
-
Revive’s (RVV.C) Bucillamine Covid-19 treatment advances through development pipeline
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions.
-
Valeo Pharma (VPH.c) and why you should care about bioflavonoids
Doing what we do at Equity Guru, every day, we receive emails and dms from shareholders of different companies – all expressing their grievances. Disgruntled with various issues such as failed management promises, lackluster progress, heavily diluted share structure, etc… As a result, it makes it even more satisfying to introduce our audience to companies…
-
Willow Biosciences (WLLW.T) takes the romance (and risk) out of cannabinoid production
Willow Biosciences (WLLW.T) is a Canadian biotech company based in Vancouver, BC, that is using “a proprietary yeast strain laboratory process” to produce commercial quantities of CBD and CBG”.
-
Revive (RVV.C) advances drug delivery tech for psychedelics
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
-
Heritage Cannabis (CANN.C) acquires Opticann – to create an international medical footprint
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”.